BIM
ESPR

Bogle Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Bogle Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-74,961
Closed -$1.04M – 352
2016
Q3 		$1.04M Buy
+74,961
New +$850K 0.07% 256
2015
Q2 		– Sell
-74,291
Closed -$6.88M – 377
2015
Q1 		$6.88M Sell
74,291
-47,035
-39% -$3.04M 0.47% 79
2014
Q4 		$4.91M Buy
+121,326
New +$3.71M 0.33% 107

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bogle Investment Management's ESPR Position: Q4 2016 in Review

Bogle Investment Management sold out of Esperion Therapeutics (ESPR) in Q4 2016, closing a stake of 74,961 shares — an estimated $1.04M sold.

Bogle Investment Management first reported a position in ESPR in Q4 2014 and held it in 3 quarters. The position peaked at $6.88M in Q1 2015. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

  • Bogle Investment Management reported no remaining Esperion Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Bogle Investment Management sold 74,961 Esperion Therapeutics shares in Q4 2016, an estimated $1.04M.
  • Bogle Investment Management first reported a position in Esperion Therapeutics in Q4 2014 and held it in 3 quarters.
  • Bogle Investment Management's Esperion Therapeutics position peaked at $6.88M in Q1 2015.
  • 99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on Bogle Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.